je.st
news
FDA panel rejects Merck claim Zetia/Vytorin cut heart risk
2015-12-15 10:29:34| Biotech - Topix.net
Dec 14 Merck & Co should not be allowed to claim that its cholesterol-lowering drugs Zetia and Vytorin reduce the risk of heart attacks and strokes in patients with coronary heart disease, an advisory committee to the U.S. Food and Drug Administration concluded on Monday.
Tags: heart
risk
cut
panel
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||